嗜黏蛋白阿克曼氏菌与肝损伤关系的研究进展

刘利敏; 姚明解; 胡端敏

doi:10.3969/j.issn.1001-5256.2020.09.051

嗜黏蛋白阿克曼氏菌与肝损伤关系的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.09.051

1. 苏州大学附属第二医院消化内科
2. 盐城市第一人民医院消化内科
3. 北京大学基础医学院人体解剖学与组织胚胎学系

基金项目:

国家自然科学基金资助项目(81902115)；中国博士后科学基金(2017M620544,2018T110014)；

详细信息

中图分类号: R575
计量
- 文章访问数: 760
- HTML全文浏览量: 32
- PDF下载量: 90
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Research advances in Akkermansia muciniphila and liver injury

Department of Gastroenterology, The Second Affiliated Hospital of Soochow University

Research funding:

摘要

摘要:
病毒与非病毒因素引起的肝损伤是慢性肝病的重要阶段,肝损伤的发生机制仍是目前研究的热点。随着对肠道菌群研究的深入,大量证据表明,肠道菌群参与了肝损伤的发生、发展,研究证实嗜黏蛋白阿克曼氏菌(Akk菌)对肝损伤具有有益作用。总结了Akk菌在免疫介导的肝损伤、酒精性肝病、非酒精性脂肪性肝病中的作用及潜在机制,认为其可为肝损伤的预防及治疗提供新的方向和选择。
- 嗜黏蛋白阿克曼氏菌 /
- 肝损伤 /
- 胃肠道微生物组
Abstract:
Liver injury caused by viral and non-viral factors is an important stage of chronic liver disease,and the pathogenesis of liver injury is still a research hotspot. With the deepening of the research on gut microbiota,substantial evidence indicates that gut microbiota participates in the development and progression of liver injury,and it has been confirmed that Akkermansia muciniphila( Akk) has a beneficial effect against liver injury. This article summarizes the role and potential mechanism of Akk in immune-mediated liver injury,alcoholic liver disease,and nonalcoholic fatty liver disease. It is believed that Akk may provide new directions and choices for the prevention and treatment of liver injury.
- Akkermansia muciniphila /
- liver injury /
- gastrointestinal microbiome

HTML全文

参考文献(40)

[1] TILG H,CANI PD,MAYER EA. Gut microbiome and liver diseases[J]. Gut,2016,65(12):2035-2044.

[2] OTTMAN N,HUUSKONEN L,REUNANEN J,et al. Characterization of outer membrane proteome of akkermansia muciniphila reveals sets of novel proteins exposed to the human intestine[J]. Front Microbiol,2016,7:1157.

[3] DERRIEN M,VAUGHAN EE,PLUGGE CM,et al. Akkermansia muciniphila gen. nov.,sp. nov.,a human intestinal mucin-degrading bacterium[J]. Int J Syst Evol Microbiol,2004,54(Pt 5):1469-1476.

[4] OUWERKERK JP,van DER ARK K,DAVIDS M,et al. Adaptation of akkermansia muciniphila to the oxic-anoxic interface of the mucus layer[J]. Appl Environ Microbiol,2016,82(23):6983-6993.

[5] COLLADO MC,DERRIEN M,ISOLAURI E,et al. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants,adults,and the elderly[J]. Appl Environ Microbiol,2007,73(23):7767-7770.

[6] CHENG J,RINGEL-KULKA T,HEIKAMP-DE JONG I,et al.Discordant temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children[J]. ISME J,2016,10(4):1002-1014.

[7] BELZER C,de VOS WM. Microbes inside—from diversity to function:The case of Akkermansia[J]. ISME J,2012,6(8):1449-1458.

[8] DERRIEN M,van BAARLEN P,HOOIVELD G,et al. Modulation of mucosal immune response,tolerance,and proliferation in mice colonized by the mucin-degrader akkermansia muciniphila[J]. Front Microbiol,2011,2:166.

[9] CANI PD. Human gut microbiome:Hopes,threats and promises[J]. Gut,2018,67(9):1716-1725.

[10] RIVERA-CHVEZ F,LOPEZ CA,BUMLER AJ. Oxygen as a driver of gut dysbiosis[J]. Free Radic Biol Med,2017,105:93-101.

[11] ZHANG H,DIBAISE JK,ZUCCOLO A,et al. Human gut microbiota in obesity and after gastric bypass[J]. Proc Natl Acad Sci U S A,2009,106(7):2365-2370.

[12] PNG CW,LINDN SK,GILSHENAN KS,et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria[J]. Am J Gastroenterol,2010,105(11):2420-2428.

[13] WANG L,CHRISTOPHERSEN CT,SORICH MJ,et al. Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism[J]. Appl Environ Microbiol,2011,77(18):6718-6721.

[14] DAO MC,EVERARD A,ARON-WISNEWSKY J,et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity:Relationship with gut microbiome richness and ecology[J]. Gut,2016,65(3):426-436.

[15] PLOVIER H,EVERARD A,DRUART C,et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice[J]. Nat Med,2017,23(1):107-113.

[16] EVERARD A,BELZER C,GEURTS L,et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity[J]. Proc Natl Acad Sci U S A,2013,110(22):9066-9071.

[17] LI J,LIN S,VANHOUTTE PM,et al. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-/-Mice[J]. Circulation,2016,133(24):2434-2446.

[18] HEYMANN F,HAMESCH K,WEISKIRCHEN R,et al. The concanavalin A model of acute hepatitis in mice[J]. Lab Anim,2015,49(1 Suppl):12-20.

[19] WANG HX,LIU M,WENG SY,et al. Immune mechanisms of Concanavalin A model of autoimmune hepatitis[J]. World J Gastroenterol,2012,18(2):119-125.

[20] WU W,LV L,SHI D,et al. Protective effect of akkermansia muciniphila against immune-mediated liver injury in a mouse model[J]. Front Microbiol,2017,8:1804.

[21] LI J,CHEN K,LI S,et al. Pretreatment with fucoidan from fucus vesiculosus protected against Con A-induced acute liver injury by inhibiting both intrinsic and extrinsic apoptosis[J].PLo S One,2016,11(4):e0152570.

[22] SONG E,LEE SK,WANG J,et al. RNA interference targeting Fas protects mice from fulminant hepatitis[J]. Nat Med,2003,9(3):347-351.

[23] ZHENG SJ,WANG P,TSABARY G,et al. Critical roles of TRAIL in hepatic cell death and hepatic inflammation[J]. J Clin Invest,2004,113(1):58-64.

[24] MALHI H,BARREYRO FJ,ISOMOTO H,et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity[J]. Gut,2007,56(8):1124-1131.

[25] LUKOVAC S,BELZER C,PELLIS L,et al. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids[J]. m Bio,2014,5(4):e01438-14.

[26] SHIN NR,LEE JC,LEE HY,et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice[J].Gut,2014,63(5):727-735.

[27] BAJAJ JS,HEUMAN DM,HYLEMON PB,et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. J Hepatol,2014,60(5):940-947.

[28] MARA U',MARGARET L,LETICIA M. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflflammation in cirrhotic rats[J]. J Hepatol,2016,64(5):1049-1057.

[29] CARIO E,GERKEN G,PODOLSKY DK. Toll-like receptor 2controls mucosal inflammation by regulating epithelial barrier function[J]. Gastroenterology,2007,132(4):1359-1374.

[30] MUCCIOLI GG,NASLAIN D,BCKHED F,et al. The endocannabinoid system links gut microbiota to adipogenesis[J]. Mol Syst Biol,2010,6:392.

[31] FUSUNYAN RD,QUINN JJ,FUJIMOTO M,et al. Butyrate switches the pattern of chemokine secretion by intestinal epithelial cells through histone acetylation[J]. Mol Med,1999,5(9):631-640.

[32] CIARLO E,HEINONEN T,HERDERSCHEE J,et al. Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo[J]. Sci Rep,2016,6:37944.

[33] GRANDER C,ADOLPH TE,WIESER V,et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease[J]. Gut,2018,67(5):891-901.

[34] TILG H,MOSCHEN AR,SZABO G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Hepatology,2016,64(3):955-965.

[35] BASHIARDES S,SHAPIRO H,ROZIN S,et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab,2016,5(9):782-794.

[36] KIM S,LEE Y,KIM Y,et al. Akkermansia muciniphila prevents fatty liver disease,decreases serum triglycerides,and maintains gut homeostasis[J]. Appl Environ Microbiol,2020,86(7).

[37] ASAOKA Y,TERAI S,SAKAIDA I,et al. The expanding role of fish models in understanding non-alcoholic fatty liver disease[J]. Dis Model Mech,2013,6(4):905-914.

[38] DAI X,WANG B. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease[J]. Gastroenterol Res Pract,2015,2015:287348.

[39] ARON-WISNEWSKY J,GABORIT B,DUTOUR A,et al. Gut microbiota and non-alcoholic fatty liver disease:New insights[J]. Clin Microbiol Infect,2013,19(4):338-348.

[40] JACKSON MA,GOODRICH JK,MAXAN ME,et al. Proton pump inhibitors alter the composition of the gut microbiota[J]. Gut,2016,65(5):749-756.

施引文献

资源附件(0)

访问统计